samedan logo
 
 
 
spacer
home > ebr > summer 2018 > natural intelligence looks at ai
PUBLICATIONS
European Biopharmaceutical Review

Natural Intelligence Looks at AI

Artificial intelligence (AI) is the fourth industrial revolution. Machinelearning, Big Data, and basic science have reached a tipping point where the question is not if, but when. Media coverage of AI is abuzz with driverless cars, facial recognition, and data analytics. However, public reception is divided. Is it a positive transformation of the human condition or a brave new world? Nations and industries alike have embraced AI, fearing to be left behind in the race for global competitive advantage.

AI is now being adopted by all the major biopharmaceutical companies at every stage of their pipeline workflows. Industrial and academic research centres and a spate of new startups and investors are all sprinting towards this new reality. Still, the hype and skepticism surrounding biotechnology applications of AI echoes earlier paradigm shifts in the drug discovery – high throughput screening, molecular modelling, and rational design. Critics say these never lived up to the promise, yet they continue to play an important role in drug discovery today.

What Is AI?

AI consists of software systems based on the confluence of computing power, large data sets, and models that mimic the understanding of the human brain. They attempt to self-learn from training sets of data and develop the ability to interpret new inputs. They provide reasoned outputs and predictions in new situations. These learning engines are model-free. Cause-and-effect is not as obvious as one might expect in a linear regression or a decision tree. Simultaneously, they achieve a high level of predictive accuracy in datasets that are too large and multidimensional for an individual to handle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a Chinawatcher, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement